Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

CompetitiveAnesthesiaMedical DevicesSafety Signal

Draeger Issues Correction for A350 and A350XL Anesthesia Machines Due to Ventilator Failure Risk

The correction of Draeger's anesthesia machines due to a high-severity ventilator failure risk poses significant reputational and competitive challenges. This situation necessitates close monitoring of Draeger's market position and competitor responses to assess potential shifts in market dynamics.

Published: June 20, 2026
Updated: June 20, 2026
Author: Humanexa Intelligence
Therapeutic area: Anesthesia / Medical Devices
Asset: Draeger
Competitive LandscapeCMP
A350 Anesthesia Machine

Focal Asset

Draeger

A350XL Anesthesia Machine

Focal Asset

Draeger

Indication

Anesthesia / Medical Devices

Signal Score

8.4

Signal assessment

Signal strength

high

Confidence level

high

Signalhigh
Confidencehigh

Strategic implication

The correction of Draeger's anesthesia machines due to a high-severity ventilator failure risk poses significant reputational and competitive challenges. This situation necessitates close monitoring of Draeger's market position and competitor responses to assess potential shifts in market dynamics.

Why it matters

The correction of Draeger's anesthesia machines due to a high-severity ventilator failure risk poses significant reputational and competitive challenges. This situation necessitates close monitoring of Draeger's market position and competitor responses to assess potential shifts in market dynamics.

What changed

Safety Signal

Analysis

Draeger, Inc. is correcting additional anesthesia workstations due to a manufacturing error that may lead to ventilator failure.

The correction of Draeger's anesthesia machines due to a high-severity ventilator failure risk poses significant reputational and competitive challenges. This situation necessitates close monitoring of Draeger's market position and competitor responses to assess potential shifts in market dynamics.

Monitor for further updates on the extent of the correction and any regulatory actions taken by the FDA.

Related companies & assets

Assets

  • Draeger →
  • A350 Anesthesia Machine →
  • A350XL Anesthesia Machine →

Sources & Humanexa intelligence

Source links

  • Draeger Issues Correction for A350 and A350XL Anesthesia Machines Due to Ventilator Failure Risk ↗

Related Humanexa pages

  • Draeger Issues Correction for A350 and A350XL Anesthesia Machines Due to Ventilator Failure Risk →

Related signals

Competitive LandscapeCMP

Focal Asset

Emerging

Focal Asset

Emerging

Indication

Oncology / CAR-T

Signal Score

8.2

Competitivehigh signal

Emerging Trends in CAR-T Immunotherapy Research for Breast Cancer Identified

A bibliometric analysis reveals significant research activity in CAR-T immunotherapy for breast cancer, highlighting key contributors and emerging hotspots.

June 21, 2026Read signal →
Competitive LandscapeCMP
DrugMOA / CompanyStage
DivalproexLupinLead

Focal Asset

Divalproex

Company

Lupin

Indication

Neurology / Antiepileptic

Signal Score

8.2

Competitivehigh signal

Lupin's Divalproex Sodium ANDA209286 Receives Abbreviated Approval

Lupin has received an abbreviated approval for its ANDA209286 application for Divalproex Sodium.

June 19, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.